As of May 27
| -0.14 / -8.81%|
The 1 analysts offering 12-month price forecasts for Aviragen Therapeutics Inc have a median target of 6.00, with a high estimate of 6.00 and a low estimate of 6.00. The median estimate represents a +313.79% increase from the last price of 1.45.
The current consensus among 1 polled investment analysts is to Buy stock in Aviragen Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.